Cardio Diagnostics Holdings, Inc. (CDIO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Cardio Diagnostics Holdings, Inc. is a medical technology company developing AI-driven DNA biomarker testing for cardiovascular disease. The company operates as a single segment focused on product testing, primarily offering the Epi+Gen CHD and PrecisionCHD tests. The financial statements reflect a 1-for-30 reverse stock split effective May 12, 2025, with all prior period data retroactively adjusted.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $7,475 | $7,870 | $8,415 | $23,798 |
| Net Loss | $(1,683,199) | $(1,287,995) | $(3,318,263) | $(5,451,579) |
| Loss Per Share (Basic/Diluted) | $(0.97) | $(1.71) | $(1.94) | $(7.49) |
| Cash and Equivalents (End of Period) | $7,966,500 (as of June 30, 2025) | |||
| Total Assets | ||||
| Total Liabilities | $671,848 | |||
| Stockholders' Equity | $9,724,699 | |||
| Operating Cash Flow (6 Months) | $(2,971,566) Used |
Material Changes vs. Prior Period
- Revenue Decline: YTD revenue decreased by approximately 65% compared to the prior year ($8,415 vs. $23,798). Management attributes the Q1 decline to the conclusion of a specific testing initiative with Family Medicine Specialists, though Q2 revenue indicates continued onboarding of new providers.
- Net Loss Reduction: While Q2 net loss increased by $395,204 year-over-year due to higher personnel costs, the YTD net loss decreased significantly by $2.13 million. This improvement is primarily driven by a massive reduction in stock-based compensation expenses ($61,390 in 2025 vs. $2.55 million in 2024).
- Expense Structure: Selling, General, and Administrative (SG&A) expenses increased in Q2 2025 compared to Q2 2024, driven by higher payroll, legal, and R&D costs. However, YTD SG&A expenses were lower than the prior year due to the aforementioned stock compensation variance.
- Liquidity: Cash balances increased slightly to $7.97 million, supported by net proceeds of $3.42 million from the sale of common stock under an At-the-Market (ATM) issuance agreement.
Outlook, Risks, and Contingencies
- Capital Needs: The company expects to continue incurring losses and negative operating cash flows. It relies on the ATM offering and potential future equity/debt issuances to fund operations, laboratory setup, and FDA submission activities. Management notes that raising capital at current stock prices presents dilution challenges.
- Regulatory Update: A federal district court vacated the FDA's final rule regarding Laboratory Developed Tests (LDTs) on March 31, 2025. The court ruled that LDTs do not meet the definition of a medical device, removing the requirement for premarket authorization that was set to phase in May 2025.
- Legal Contingencies:
- Boustead Securities: Dispute regarding success fees from a terminated 2021 agreement. The company disputes the claim and believes no material adverse impact will occur.
- The Benchmark Company: Alleged damages regarding a right of first refusal for a prior transaction. The company is evaluating the claim.
- Securities Law Firm: A demand letter regarding the S-4 Registration Statement remains unresolved, though no lawsuit has been filed.
- Internal Controls: Management identified a material weakness in internal controls due to inadequate segregation of duties. Remediation plans, including approval matrices and automation, are in progress but not yet fully implemented.
Investor Verification Checklist
- Revenue Sustainability: Verify the pipeline of new provider contracts to confirm if Q2 revenue represents a sustainable trend or a temporary fluctuation following the Q1 initiative conclusion.
- Cash Runway: Assess the sufficiency of the $7.97 million cash balance against the projected burn rate, considering the need to fund the new laboratory facility and ongoing R&D.
- Dilution Risk: Monitor the terms and volume of future equity issuances under the ATM agreement and the proposed 20% share issuance proposal for the upcoming annual meeting.
- Legal Exposure: Track the status of the Boustead Securities and Benchmark Company disputes to ensure no unexpected liabilities materialize.
- Control Remediation: Confirm the timeline for fully implementing the remediation of the material weakness in internal controls over financial reporting.